Clinical Trials Logo

Gastroesophageal Cancer clinical trials

View clinical trials related to Gastroesophageal Cancer.

Filter by:

NCT ID: NCT05438940 Recruiting - Clinical trials for GastroEsophageal Cancer

Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Gastroesophageal Cancer (GEC) Patients

STRONG-GEC
Start date: July 15, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to assess the feasibility and patient satisfaction with the Support through Remote Observation and Nutrition Guidance (STRONG) program. The program provides nutrition support for participants living with gastroesophageal cancer who are receiving chemotherapy and radiation treatment

NCT ID: NCT05427487 Recruiting - Colorectal Cancer Clinical Trials

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Start date: February 17, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1 open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 in people with micro satellite-stable (MSS) colorectal or gastroesophageal cancer metastatic to liver, or advanced ovarian cancer.

NCT ID: NCT05379972 Recruiting - Gastric Cancer Clinical Trials

Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers

Start date: January 12, 2023
Phase: Phase 2
Study type: Interventional

This study is an open-label, phase II study with a safety lead-in to assess the response rate of induction olaparib and stereotactic beam radiotherapy (SBRT) followed by combination olaparib/pembrolizumab in patients with metastatic gastric and GEJ cancers after at least one of therapy.

NCT ID: NCT05338060 Recruiting - Clinical trials for GastroEsophageal Cancer

A Systems Approach to Immunotherapy Biomarker Identification Within the Postoperative Wound-Healing Microenvironment in Patients With Gastroesophageal Cancer

BAISIC
Start date: January 26, 2022
Phase:
Study type: Observational

The purpose of this research is to collect surgical drain fluid and blood from patients who have undergone surgery for gastric or esophageal cancer, and to analyze the fluid and blood using a variety of laboratory techniques for molecular markers capable of predicting response to immunotherapy.

NCT ID: NCT05205343 Recruiting - Clinical trials for GastroEsophageal Cancer

Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

Start date: May 11, 2022
Phase:
Study type: Observational

To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.

NCT ID: NCT05122091 Recruiting - Gastric Cancer Clinical Trials

Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma

Start date: November 5, 2021
Phase: Phase 2
Study type: Interventional

For locally advanced gastric/gastroesophageal junction adenocarcinoma (cT3/4aN+M0 ), neoadjuvant therapy can downstage T and N stage, improve R0 resection rate, reduce recurrence and metastasis rates, and finally improve the long-term survival. A combination of Fruquintinib and SOX for locally advanced gastric/gastroesophageal junction adenocarcinoma could be a novel therapy. This study intends to evaluate the efficacy of Fruquintinib plus SOX as neoadjuvant therapy for locally advanced gastric or gastroesophageal junction adenocarcinoma.

NCT ID: NCT05098132 Recruiting - Gastric Cancer Clinical Trials

Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors

Start date: January 25, 2022
Phase: Phase 1
Study type: Interventional

This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors.

NCT ID: NCT04688801 Recruiting - Esophageal Cancer Clinical Trials

Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer

Start date: July 1, 2020
Phase: N/A
Study type: Interventional

Surgery with or without neoadjuvant therapy is usually used as the treatment for resectable esophageal cancer or esophageal- gastric junction cancer. Patients who have a poor response to neoadjuvant therapy and have an incomplete (R1) resection or have metastatic lymph nodes in the resection specimen (N+) are especially at risk of recurrence, to continue with the chemotherapy± radiotherapy is often used in these cases. However, the overall survival is still poor. We designed a prospective randomized controlled tial to study whether immunotherapy could be used with chemotherapy after surgery to improve overall survival. The primary endpoint ofthe study is disease free survival, with secondary endpoints of overall survival, safety and toxicity, and quality of life.

NCT ID: NCT04385641 Recruiting - Clinical trials for Gastroesophageal Cancer

Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer

Start date: October 8, 2019
Phase: N/A
Study type: Interventional

This study is an open, single infusion, cell infusion dose /method exploration study. In patients with gastric cancer and gastroesophageal cancer without effective treatment, the safety of UCB-NK cell immunotherapy was evaluated and the preliminary curative effect results were obtained.

NCT ID: NCT04281576 Recruiting - Gastric Cancer Clinical Trials

Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Chemotherapy as First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma

Start date: December 19, 2019
Phase: N/A
Study type: Interventional

The study is a prospective, single arm, phase II trial aimed to evaluate the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with XELOX for the treatment of unresectable, locally advanced or metastatic Gastroesophageal Junction (GEJ) or Gastric (GC) Adenocarcinoma who were previously untreated with systemic therapy. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.